Limits...
Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry.

Witzel I, Müller V, Abenhardt W, Kaufmann M, Schoenegg W, Schneeweis A, Jänicke F - BMC Cancer (2014)

Bottom Line: Overall, 47.1% of patients (95% confidence interval (CI): 39.9-54.1%) remained in remission for more than 5 years, while the median time to progression was 4.5 years (95% CI: 4.0-6.6 years).Interruption of trastuzumab therapy correlated with shorter time to progression.HER2-positive patients, who initially respond to palliative treatment with trastuzumab, can achieve a long-term tumor remission of several years.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynecology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D- 20246 Hamburg, Germany. iwitzel@uke.de.

ABSTRACT

Background: In this study, we examined patients who had non-progressive disease for at least 2 years after diagnosis of inoperable locoregional recurrent or metastatic breast cancer under continuous trastuzumab treatment. Our primary goal was to assess the long-term outcome of patients with durable response to trastuzumab.

Methods: 268 patients with HER2-positive inoperable locally recurrent or metastatic breast cancer and non-progressive disease for at least 2 years under trastuzumab treatment were documented retrospectively or prospectively in the HER-OS registry, an online documentation tool, between December 2006 and September 2010 by 71 German oncology centers. The study end point was time to tumor progression.

Results: Overall, 47.1% of patients (95% confidence interval (CI): 39.9-54.1%) remained in remission for more than 5 years, while the median time to progression was 4.5 years (95% CI: 4.0-6.6 years). Lower age (<50 years) and good performance status (ECOG 0) at time of trastuzumab treatment initiation as well as complete remission after initial trastuzumab treatment were associated with longer time to progression. Interruption of trastuzumab therapy correlated with shorter time to progression.

Conclusions: HER2-positive patients, who initially respond to palliative treatment with trastuzumab, can achieve a long-term tumor remission of several years.

Show MeSH

Related in: MedlinePlus

Probability of progression during palliative trastuzumab treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4230522&req=5

Fig1: Probability of progression during palliative trastuzumab treatment.

Mentions: Until the end of the study, 126 patients (47.0%) had progressive disease during continuous trastuzumab treatment with an estimated median time to progression (TTP) of 4.5 years (95% CI: 4.0–6.6 years). It was estimated that 47.1% of patients (95% CI: 39.9–54.1%) remained in remission for more than 5 years, 40.5% (95% CI: 32.1–48.7%) for more than 7 years, and 29.2% (95% CI: 15.1–44.8%) for more than 9 years (Table 3, Figure 1).Table 3


Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry.

Witzel I, Müller V, Abenhardt W, Kaufmann M, Schoenegg W, Schneeweis A, Jänicke F - BMC Cancer (2014)

Probability of progression during palliative trastuzumab treatment.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4230522&req=5

Fig1: Probability of progression during palliative trastuzumab treatment.
Mentions: Until the end of the study, 126 patients (47.0%) had progressive disease during continuous trastuzumab treatment with an estimated median time to progression (TTP) of 4.5 years (95% CI: 4.0–6.6 years). It was estimated that 47.1% of patients (95% CI: 39.9–54.1%) remained in remission for more than 5 years, 40.5% (95% CI: 32.1–48.7%) for more than 7 years, and 29.2% (95% CI: 15.1–44.8%) for more than 9 years (Table 3, Figure 1).Table 3

Bottom Line: Overall, 47.1% of patients (95% confidence interval (CI): 39.9-54.1%) remained in remission for more than 5 years, while the median time to progression was 4.5 years (95% CI: 4.0-6.6 years).Interruption of trastuzumab therapy correlated with shorter time to progression.HER2-positive patients, who initially respond to palliative treatment with trastuzumab, can achieve a long-term tumor remission of several years.

View Article: PubMed Central - PubMed

Affiliation: Department of Gynecology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, D- 20246 Hamburg, Germany. iwitzel@uke.de.

ABSTRACT

Background: In this study, we examined patients who had non-progressive disease for at least 2 years after diagnosis of inoperable locoregional recurrent or metastatic breast cancer under continuous trastuzumab treatment. Our primary goal was to assess the long-term outcome of patients with durable response to trastuzumab.

Methods: 268 patients with HER2-positive inoperable locally recurrent or metastatic breast cancer and non-progressive disease for at least 2 years under trastuzumab treatment were documented retrospectively or prospectively in the HER-OS registry, an online documentation tool, between December 2006 and September 2010 by 71 German oncology centers. The study end point was time to tumor progression.

Results: Overall, 47.1% of patients (95% confidence interval (CI): 39.9-54.1%) remained in remission for more than 5 years, while the median time to progression was 4.5 years (95% CI: 4.0-6.6 years). Lower age (<50 years) and good performance status (ECOG 0) at time of trastuzumab treatment initiation as well as complete remission after initial trastuzumab treatment were associated with longer time to progression. Interruption of trastuzumab therapy correlated with shorter time to progression.

Conclusions: HER2-positive patients, who initially respond to palliative treatment with trastuzumab, can achieve a long-term tumor remission of several years.

Show MeSH
Related in: MedlinePlus